These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35196966)

  • 1. Structure-based pharmacophore mapping and virtual screening of natural products to identify polypharmacological inhibitor against c-MET/EGFR/VEGFR-2.
    Varma DA; Singh M; Wakode S; Dinesh NE; Vinaik S; Asthana S; Tiwari M
    J Biomol Struct Dyn; 2023 Apr; 41(7):2956-2970. PubMed ID: 35196966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches.
    Jethwa M; Gangopadhyay A; Saha A
    J Biomol Struct Dyn; 2023 Mar; 41(5):1681-1689. PubMed ID: 35014597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of
    Ejaz SA; Aziz M; Fawzy Ramadan M; Fayyaz A; Bilal MS
    Molecules; 2023 May; 28(10):. PubMed ID: 37241785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of new potential CDK2/VEGFR2 type II inhibitors by fragmentation and virtual screening of natural products.
    Vásquez AF; Reyes Muñoz A; Duitama J; González Barrios A
    J Biomol Struct Dyn; 2021 Jun; 39(9):3285-3299. PubMed ID: 32362218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis.
    Sharma N; Sharma M; Shakeel E; Jamal QMS; Kamal MA; Sayeed U; Khan MKA; Siddiqui MH; Arif JM; Akhtar S
    Med Chem; 2018; 14(6):626-640. PubMed ID: 29663896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative structure activity relationship and molecular simulations for the exploration of natural potent VEGFR-2 inhibitors: an
    Sharma N; Sharma M; Rahman QI; Akhtar S; Muddassir M
    J Biomol Struct Dyn; 2021 May; 39(8):2806-2823. PubMed ID: 32363995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. '
    H Ibraheim M; Maher I; Khater I
    J Biomol Struct Dyn; 2024 Nov; 42(18):9571-9586. PubMed ID: 37753739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based pharmacophore modeling, virtual screening and simulation studies for the identification of potent anticancerous phytochemical lead targeting cyclin-dependent kinase 2.
    Sharma M; Sharma N; Muddassir M; Rahman QI; Dwivedi UN; Akhtar S
    J Biomol Struct Dyn; 2022; 40(20):9815-9832. PubMed ID: 34151738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation.
    Raafat A; Mowafy S; Abouseri SM; Fouad MA; Farag NA
    Comput Biol Med; 2022 Jul; 146():105526. PubMed ID: 35487125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of ligand and structure-based pharmacophore screening for the identification of novel natural leads against Euchromatic histone lysine methyltransferase 2 (EHMT2/G9a).
    Jana A; Naga R; Saha S; Griñán-Ferré C; Banerjee DR
    J Biomol Struct Dyn; 2024 Apr; 42(7):3535-3562. PubMed ID: 37216299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19.
    Fayyazi N; Mostashari-Rad T; Ghasemi JB; Ardakani MM; Kobarfard F
    J Biomol Struct Dyn; 2022; 40(22):11787-11808. PubMed ID: 34405765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor potentially stable conformations from molecular dynamics as a structure-based pharmacophore model for mapping, screening, and identifying ligands-a new paradigm shift in pharmacophore screening.
    Shanmugarajan D; David C
    J Biomol Struct Dyn; 2023 Jul; 41(11):4939-4948. PubMed ID: 35543232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
    Bhojwani HR; Joshi UJ
    Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantum evaluation and therapeutic activity of (E)-N-(4-methoxyphenyl)-2-(4-(3-oxo-3-phenylprop-1-en-1-yl) phenoxy)acetamide and its modified derivatives against EGFR and VEGFR-2 in the treatment of triple-negative cancer via in silico approach.
    Ipinloju N; Ibrahim A; da Costa RA; Adigun TB; Olubode SO; Abayomi KJ; Aiyelabegan AO; Esan TO; Muhammad SA; Oyeneyin OE
    J Mol Model; 2023 Apr; 29(5):159. PubMed ID: 37099048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.
    Rampogu S; Baek A; Zeb A; Lee KW
    BMC Cancer; 2018 Mar; 18(1):264. PubMed ID: 29514608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation.
    Hou J; Zou Q; Wang Y; Gao Q; Yao W; Yao Q; Zhang J
    J Biomol Struct Dyn; 2019 Aug; 37(12):3135-3149. PubMed ID: 30079817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations.
    Ashiru MA; Ogunyemi SO; Temionu OR; Ajibare AC; Cicero-Mfon NC; Ihekuna OA; Jagun MO; Abdulmumin L; Adisa QK; Asibor YE; Okorie CJ; Lawal MO; Babalola MO; Abdulrasaq IT; Salau LB; Olatunji IO; Bankole MA; Daud AB; Adeyemi AO
    J Mol Model; 2023 Apr; 29(5):128. PubMed ID: 37016200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of potentially high drug-like VEGFR2/c-Met dual-target type II kinase inhibitors with symmetric skeletons based on structural screening.
    Xie J; Zhang X; Meng D; Li Y; Deng P
    J Biomol Struct Dyn; 2024; 42(3):1249-1267. PubMed ID: 37042992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.